Zobrazeno 1 - 10 of 67 pro vyhledávání: '"Vincenzo, Martinelli"'
1
Akademický článek
Optical coherence tomography angiography features in Waldenström macroglobulinemia patients without Hyperviscosity syndrome: A pilot prospective study
Autor: Gilda Cennamo, Michele Rinaldi, Alessandro Severino, Laura De Fazio, Emanuele Malvone, Vincenzo Martinelli, Ciro Costagliola
Publikováno v: Photodiagnosis and Photodynamic Therapy, Vol 48, Iss , Pp 104264- (2024)
Purpose: To evaluate the retinal vessel density (VD) with optical coherence tomography angiography (OCTA) in asymptomatic patients affected by Waldenström macroglobulinemia (WM) without hyperviscosity syndrome (HVS) and to highlight the presence of
Externí odkaz: https://doaj.org/article/0aa157cf75fa48e2b0ab17019d8a1d1f
Zobrazit plný text záznamu
4
Akademický článek
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
Autor: Alessandro Rambaldi, Alessandra Iurlo, Alessandro M. Vannucchi, Bruno Martino, Attilio Guarini, Marco Ruggeri, Nikolas von Bubnoff, Marianna De Muro, Mary Frances McMullin, Stefania Luciani, Vincenzo Martinelli, Axel Nogai, Vittorio Rosti, Alessandra Ricco, Paolo Bettica, Sara Manzoni, Silvia Di Tollo
Publikováno v: Blood Cancer Journal, Vol 11, Iss 3, Pp 1-7 (2021)
Abstract Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow, mainly due to a Janus kinase 2 gene mutation (J
Externí odkaz: https://doaj.org/article/d1cf3734083241139c159412ffeebaaf
Zobrazit plný text záznamu
5
Akademický článek
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
Autor: Novella Pugliese, Claudia Giordano, Davide Nappi, Luigiana Luciano, Claudio Cerchione, Mario Annunziata, Beniamino Casale, Elena Crisà, Maria Rosaria Villa, Luca Pezzullo, Maria Iovine, Marco Picardi, Francesco Grimaldi, Fabrizio Pane, Vincenzo Martinelli
Publikováno v: Cancer Medicine, Vol 8, Iss 6, Pp 2802-2809 (2019)
Abstract Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF). However, no clear survival benefit has been
Externí odkaz: https://doaj.org/article/b6887bdff7b64bdeb31418e1cb8b170a
Zobrazit plný text záznamu
6
Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia
Autor: Elena Inzoli, Elena Crisà, Novella Pugliese, Ivan Civettini, Giuseppe Lanzarone, Andrea Castelli, Vincenzo Martinelli, Laura Montelisciani, Laura Antolini, Carlo Gambacorti‐Passerini, Elena Maria Elli
Publikováno v: European Journal of Haematology. 110:354-361
Objectives: Erythropoiesis-stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B-ESA), in myelofibrosis (MF) is not well established.Methods: This study
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fefb8a6a323e25d68e37639bd50d6e5
https://doi.org/10.1111/ejh.13910
Zobrazit plný text záznamu
7
GATA‐1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis
Autor: James Lally, Christian Marinaccio, Lilia Brown, Vincenzo Martinelli, Vishaka Sovani, Ciro Roberto Rinaldi, Ciaren Graham, Kristian Boasman, John D. Crispino, Ilaria Cappuccio
Publikováno v: Lally, J, Brown, L, Martinelli, V, Cappuccio, I, Sovani, V, Marinaccio, C, Crispino, J D, Graham, C, Rinaldi, C & Boasman, K 2019, ' GATA-1 a potential novel biomarker for the differentiation of essential thrombocythaemia and myelofibrosis ', Journal of Thrombosis and Haemostasis . https://doi.org/10.1111/jth.14433
Essentials The BCR-ABL negative myeloproliferative neoplasms are subjected to unknown phenotypic modifiers. GATA-1 is upregulated in ET patients, regardless of treatment regimen or mutational status. Myelofibrosis (MF) megakaryocytes displayed decrea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9197f3f537f3c188779be270e46e4af0
https://doi.org/10.1111/jth.14433
Zobrazit plný text záznamu
8
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
Autor: Maria Rosaria Villa, Francesco Grimaldi, Davide Nappi, Mario Annunziata, Elena Crisà, Fabrizio Pane, Luigiana Luciano, L Pezzullo, Claudia Giordano, Novella Pugliese, Beniamino Casale, Marco Picardi, Maria Iovine, Claudio Cerchione, Vincenzo Martinelli
Publikováno v: Cancer Medicine, Vol 8, Iss 6, Pp 2802-2809 (2019)
Cancer Medicine
Background Ruxolitinib (Ruxo), an orally bioavailable and selective inhibitor of JAK1 and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF). However, no clear survival benefit has been demonstra
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ede8446a6e588dbd9f05de571ef8846
https://doaj.org/article/b6887bdff7b64bdeb31418e1cb8b170a
Zobrazit plný text záznamu
9
A novel ultrasound-based approach to investigate extramedullary haematopoiesis in foetal spleen
Autor: Marcello, Roberto, Gianmario, Pasqualone, Nicola G, Di Donato, Zaheer, Malik, Sheereen, Bhaiyat, Vito Ca, Caponio, Giuseppe, Lillo, Gianfranco, Vallone, Ciro R, Rinaldi, Vincenzo, Martinelli
Publikováno v: Am J Blood Res
Foetal spleen is described as a transient focus of haematopoiesis between the 3(rd) and 5(th) month of gestation: this function is however entirely replaced by the bone marrow before the end of pregnancy. This study identifies haematopoiesis in foeta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::672a28e4689b8dd07cb4dcbc34f502bc
https://europepmc.org/articles/PMC8010597/
Zobrazit plný text záznamu
10
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
Autor: Bruno Martino, Sara Manzoni, Vincenzo Martinelli, Alessandra Iurlo, Attilio Guarini, Mary Frances McMullin, Marianna De Muro, Silvia Di Tollo, Alessandro M. Vannucchi, Marco Ruggeri, Axel Nogai, Vittorio Rosti, Paolo Bettica, Alessandro Rambaldi, Stefania Luciani, Nikolas von Bubnoff, Alessandra Ricco
Publikováno v: Rambaldi, A, Iurlo, A, Vannucchi, A M, Martino, B, Guarini, A, Ruggeri, M, von Bubnoff, N, De Muro, M, McMullin, M F, Luciani, S, Martinelli, V, Nogai, A, Rosti, V, Ricco, A, Bettica, P, Manzoni, S & Di Tollo, S 2021, ' Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program ', Blood cancer journal, vol. 11, 53 . https://doi.org/10.1038/s41408-021-00445-z
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-7 (2021)
Blood Cancer Journal
Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow, mainly due to a Janus kinase 2 gene mutation (JAK2V617F)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb60d2bf78685d815643b5fb66dd646a
https://hdl.handle.net/11588/908066
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje